Compare · GILD vs SLXN
GILD vs SLXN
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Silexion Therapeutics Corp (SLXN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SLXN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 60782.9x SLXN ($2.7M).
- Over the past year, GILD is up 24.1% and SLXN is down 97.9% - GILD leads by 122.0 points.
- GILD has been more active in the news (7 items in the past 4 weeks vs 4 for SLXN).
- GILD has more recent analyst coverage (25 ratings vs 0 for SLXN).
- Company
- Gilead Sciences Inc.
- Silexion Therapeutics Corp
- Price
- $134.23-1.50%
- $2.58+1.18%
- Market cap
- $166.72B
- $2.7M
- 1M return
- +5.49%
- -3.73%
- 1Y return
- +24.06%
- -97.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest SLXN
- SEC Form DEFA14A filed by Silexion Therapeutics Corp
- Amendment: SEC Form SCHEDULE 13D/A filed by Silexion Therapeutics Corp
- Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
- SEC Form EFFECT filed by Silexion Therapeutics Corp
- SEC Form 424B3 filed by Silexion Therapeutics Corp
- SEC Form DEF 14A filed by Silexion Therapeutics Corp
- Silexion Therapeutics to Attend BIO International Convention 2026
- SEC Form S-3 filed by Silexion Therapeutics Corp
- CSO and CDO Shirvan Mitchell was granted 6,000 units of Ordinary Shares, increasing direct ownership by 215% to 8,789 units (SEC Form 4)
- CFO and Secretary Horenshtein Hadar Mirit was granted 7,500 units of Ordinary Shares, increasing direct ownership by 150% to 12,515 units (SEC Form 4)